参芪注射液联合化疗及顺铂胸腔灌注治疗非小细胞肺癌恶性胸水的疗效观察

兰州大学机构库 >第一临床医学院

	参芪注射液联合化疗及顺铂胸腔灌注治疗非小细胞肺癌恶性胸水的疗效观察
Alternative Title	Clinical observation of Shenqi Injection combined with docetaxel/cisplatin(DP) chemotherapy and intrapleural injection of cisplatin on non-small cell lung cancer-mediated maligant pleural effusion.
	罗亚娟
Subtype	硕士
Thesis Advisor	岳红梅
	2016-05-23
Degree Grantor	兰州大学
Place of Conferral	兰州
Degree Name	硕士
Keyword	参芪扶正注射液非小细胞肺癌化疗增效减毒恶性胸水
Abstract	目的：通过临床对比观察参芪注射液联合DP（多西他赛/顺铂）方案化疗及胸腔内注射顺铂对非小细胞肺癌（Non-small cell lung cancer，NSCLC）伴恶性胸水的临床疗效、化疗毒副反应以及生活质量等影响差异，评价其治疗效果，从而为NSCLC伴恶性胸水患者探索安全、有效的临床治疗方法，同时也为参芪注射液在肺癌的临床应用提供一定的依据。方法：将兰州大学第一医院呼吸科2013年10月至2015年3月期间，经我院病理科诊断明确的42例非小细胞肺癌伴恶性胸腔积液初治患者按入院时间先后随机分为治疗组（21例）对照组（21例），两组均采用DP方案化疗，同时胸腔引流胸水后胸腔内注入顺铂，治疗组在对照组基础上于化疗前3天开始参芪注射液静脉滴注，连用10天，21天为1个周期，共4个周期。治疗结束后观察胸水控制情况，Karnofsky(卡氏，KPS，百分法)功能状态评分变化及消化道反应、骨髓抑制等化疗毒副反应情况。结果：治疗组与对照组胸水控制有效率（PR+CR）分别为85.71％、47.62%，P＜0.05,差异有统计学意义。KPS评分改善情况治疗组明显优于对照组（P<0.05）。治疗组胃肠道反应、白细胞下降发生率明显低于对照组，有统计学意义（P<0.05）。结论：对NSCLC伴恶性胸腔积液患者采用参芪扶正注射液联合DP方案化疗及胸腔内注射顺铂可有效减少胸水产生改善患者临床症状及生活质量，并减轻化疗毒副反应。关键词：参芪扶正注射液；非小细胞肺癌；化疗；增效减毒；恶性胸水
Other Abstract	Objective To observe the clinical efficacy of Shenqi injection combined DP (docetaxel / cisplatin) chemotherapy for non-small cell lung cancer by comparing the clinical efficacy, chemotherapy toxicity and the differences impact for quality of life,and try to find the scientific and theoretical basis that useing shenqi injection treament non-small cell lung cance. Method Select a total number of 42 non-small cell lung cancer patients from October 2013 to March 2015 in Respiratory period of the first Hospital of Lanzhou University,who had pleural effusion,all of them were randomly dicided into treatment group and control group,21 cases in each group. Control group was treated single chemotherapy; Treatment group were combined with intravenous infusion of shenqifuzheng injection before 3 days of the treated with chemotherapy. Evaluated the the clinical efficacy of in the treatment of pleural effusion, gastrointestnal rection and the patients’ quality of life. Results Compared with control group, the situation of pleural effusion which is controled was significantly different (85.7%,47.62%,Respectively),treatment group had a better effective than control group (P<0.05),KPS had a higher sore (P<0.05),the incidence of gastrointestinal reactions and adverse reactions was reduced(P<0.05). Conclusion Shenqifuzheng injection combined with docetaxel / cisplatin (DP) chemotherapy and intrapleural injection of cisplatin in the patients of non-small cell lung cancer (NSCLC) can effectively reduce the production of pleural effusion, improve the clinical symptoms and quality of life and reduce the toxicity of chemotherapy. Key words shenqifuzheng injection; non-small cell lung cancer; chemotherapy;synergism and attenuation; malignant pleural effusion.
URL	查看原文
Language	中文
Document Type	学位论文
Identifier	https://ir.lzu.edu.cn/handle/262010/201212
Collection	第一临床医学院
Recommended Citation GB/T 7714	罗亚娟. 参芪注射液联合化疗及顺铂胸腔灌注治疗非小细胞肺癌恶性胸水的疗效观察[D]. 兰州. 兰州大学,2016.

Files in This Item:
There are no files associated with this item.

If you have any objections to this item, please fill out the form below and the administrator will contact you as soon as possible.
Content:
Email：	*
Institution:
Verification Code:	Refresh

Any comments and suggestions are welcomed.
Title:	*
Content:
Email：	*
Verification Code:	Refresh

第一临床医学院知识库